// App-Quantinova.ai

e12513 : Safety and efficacy of eflapegrastim in reducing severe neutropenia in patients treated with myelosuppressive chemotherapy in a phase 3 randomized controlled trial compared to pegfilgrastim (ADVANCE trial).

Researchers

Presenter

  • Lee Steven Schwartzberg

Principal Investigators

  • Zandong Yang

  • Julio Antonio Peguero

  • Richy Agajanian

  • Jayaram S. Bharadwaj

  • Alvaro Restrepo

  • Osama Hlalah

  • Inderjit Mehmi

  • Gajanan Bhat

  • Patrick Wayne Cobb

Medical Centers

  • The University of Tennessee Health Science Center, Memphis, TN

  • Inovio Pharmaceuticals, Plymouth Meeting, PA

  • Oncology Consultants PA, Department of Research, Houston, TX

  • The Oncology Institute of Hope and Innovation, Downey, CA

  • Pacific Cancer Medical Center, Anaheim, CA

  • Texas Onc PA, McAllen, TX

  • Bond Clinic PA, Winter Haven, FL

  • WVU Cancer Institute of WVU Medicine, Morgantown, WV

  • Spectrum Pharmaceuticals, Irvine, CA

  • Frontier Cancer Center, Billings, MT

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Granulocyte colony-stimulating factor

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Eflapegrastim

  • Pegfilgrastim

  • Docetaxel

  • Filgrastim

Outcome

  • N/A

Study Design

  • Randomized

  • Non Inferiority

  • Controlled

Phase

  • III

Study Id's

  • NCT02643420

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved